MAPT and supranuclear palsy, progressive, 1: Conversely, though PSP has far fewer patients to enroll in trials and fewer diagnostic and response biomarkers, they are clinically distinct from other neurodegenerative diseases, follow an expected disease course, and almost always have 4R tau pathology on autopsy.